A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $533 to $585
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $350 to $376
Needham Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Biogen Analyst Ratings
Icon Price Target Cut to $350.00/Share From $355.00 by Barclays
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $282
RBC Capital Adjusts Price Target on Biogen to $282 From $303
Argenx Price Target Raised to $547.00/Share From $543.00 by Wells Fargo
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Buy Rating on Biogen: Anticipating Positive Reversal and Global Market Strength for Lecanemab
Icon Analyst Ratings
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $497 to $598
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $350 to $380
Argenx Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Truist Adjusts Price Target on ICON to $383 From $367, Maintains Buy Rating
Argenx Se (ARGX) Gets a Hold From UBS
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)